The American College of Cardiology (ACC) has announced five Late-Breaking Clinical Trial Sessions, two Late-Breaking Clinical Trial Deep Dive Sessions, and three Featured Clinical Research sessions to be presented during its annual scientific session, “ACC with WCC,” or ACC.23/WCC to be held March 4-6 in New Orleans, LA.
21.03.2022 - Late-breaking clinical trial presentation by Deepak L. Bhatt, M.D., M.P.H., will describe new analysis of rates of CV death, myocardial infarction and stroke in the SCORED trialTHE WOODLANDS, Texas, March 21, 2022 (GLOBE NEWSWIRE) - Lexicon .
Posted on 1113 Bristol Myers Squibb (NYSE: BMY) today announced a new analysis of data from the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM), which was presented at the American College of Cardiology’s 70 th Annual Scientific Session (ACC.21), with simultaneous publication in The Lancet. At 30 weeks, the change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) was greater in mavacamten patients than placebo, with similar benefits across all KCCQ subscales. Moreover, a greater proportion of mavacamten patients achieved a very large, clinically meaningful improvement (≥20 points) in the KCCQ OSS, compared to placebo, 36% [33/92] vs. 15% [13/88]. A change of at least 5 points is required to be considered clinically significant. These results were presented today as part of the Featured Clinical Research I Session (403-09) in the Hot Topics Channel from 12:15-1:30 p.m. EDT.
New analysis of EXPLORER-HCM trial assessing impact of mavacamten on patient’s health status to be presented as late-breaking oral presentation Interim results of EXPLORER long-term extension study of mavacamten safety and efficacy data in patients with obstructive hypertrophic cardiomyopathy also to be presented Bristol Myers Squibb today announced that data from multiple studies across the company’s clinical … New analysis of EXPLORER-HCM trial assessing impact of mavacamten on patient’s health status to be presented as late-breaking oral presentation Interim results of EXPLORER long-term extension study of mavacamten safety and efficacy data in patients with obstructive hypertrophic cardiomyopathy (oHCM)